Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
PLoS One. 2011 Mar 8;6(3):e17791. doi: 10.1371/journal.pone.0017791.
Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) and Trans-esophageal Ultrasound Scanning with Fine Needle Aspiration (EUS-FNA) are important, novel techniques for the diagnosis and staging of non-small cell lung cancer (NSCLC) that have been incorporated into lung cancer staging guidelines. To guide and optimize treatment decisions, especially for NSCLC patients in stage III and IV, EGFR and KRAS mutation status is often required. The concordance rate of the mutation analysis between these cytological aspirates and histological samples obtained by surgical staging is unknown. Therefore, we studied the extent to which allele-specific quantitative real-time PCR with hydrolysis probes could be reliably performed on EBUS and EUS fine needle aspirates by comparing the results with histological material from the same patient. We analyzed a series of 43 NSCLC patients for whom cytological and histological material was available. We demonstrated that these standard molecular techniques can be accurately applied on fine needle cytological aspirates from NSCLC patients. Importantly, we show that all mutations detected in the histological material of primary tumor were also identified in the cytological samples. We conclude that molecular profiling can be reliably performed on fine needle cytology aspirates from NSCLC patients.
经支气管超声引导针吸活检术（EBUS-TBNA）和经食管超声扫描细针抽吸术（EUS-FNA）是诊断和分期非小细胞肺癌（NSCLC）的重要新方法，已被纳入肺癌分期指南。为了指导和优化治疗决策，特别是对于 III 期和 IV 期 NSCLC 患者，通常需要检测 EGFR 和 KRAS 基因突变状态。这些细胞学抽吸物与通过手术分期获得的组织学样本之间的突变分析一致性率尚不清楚。因此，我们通过将结果与同一患者的组织学材料进行比较，研究了水解探针等位基因特异性实时定量 PCR 技术在 EBUS 和 EUS 细针抽吸物上可靠进行的程度。我们分析了 43 例 NSCLC 患者的细胞学和组织学材料。结果表明，这些标准的分子技术可以准确地应用于 NSCLC 患者的细针细胞学抽吸物。重要的是，我们发现组织学标本中检测到的所有突变均在细胞学样本中得到鉴定。我们得出结论，分子分析可以可靠地应用于 NSCLC 患者的细针细胞学抽吸物。
